<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01075633</url>
  </required_header>
  <id_info>
    <org_study_id>COLONFAM</org_study_id>
    <nct_id>NCT01075633</nct_id>
  </id_info>
  <brief_title>Colorectal Cancer Screening in Familiar-Risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy</brief_title>
  <acronym>COLONFAM</acronym>
  <official_title>Colorectal Cancer Screening in Familiar-Risk Population: a Randomized Control Trial Comparing Immunochemical Fecal Occult Blood Testing Versus Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enrique Quintero</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Canaria Rafael Clavijo para la Investigación Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed: 1) to compare the accuracy of colonoscopy vs immunochemical faecal
      occult blood test (iFOBT) and colonoscopy when positive for colorectal cancer (CRC) screening
      in familiar-risk population and; 2) to determine the complications associated with both
      strategies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, controlled, randomized phase III study to evaluate the
      effectiveness of the iFOBT for detecting advanced neoplasia (polyps &gt; 1cm in size, high grade
      dysplasia or with villous component, or CRC) in first degree relatives of patients with CRC.

      Index cases will be interviewed to obtain the family tree and their first-degree relatives
      will be contacted to invite them to participate in the study. Index-cases, will be randomized
      into one of the following two groups in order that their relatives receive the same screening
      strategy: A) colonoscopy; or B) annual iFOBT test (OC-Sensor®, cut off ≥50 ng/ml) and
      colonoscopy if positive. To determine the sensitivity and specificity of the iFOBT strategy,
      individuals randomized to group B will be invited to undergo a complete colonoscopy following
      two years follow-up. In addition, epidemiological data, personal history of disease, family
      history of neoplasm, characteristics of lesions at colonoscopy and histological diagnosis
      will be recorded.

      To test the hypothesis of equivalence between the iFOBT test and colonoscopy for detecting
      advanced colorectal neoplasm, it was considered a probability of participation, detection
      capability and prevalence of advanced adenomas for iFOBT of 0.750, 0.565 and 0.077,
      respectively, being the product of them 0.033. In the case of colonoscopy, the likelihood of
      participation, detection capability and prevalence of advanced adenomas in this population at
      risk are 0,500, 0.965 and 0.077, respectively, and their product 0.037. Accordingly, for a
      Type I error (alpha) of 5%, a power of 80% and a maximum deviation between the probabilities
      of the two tests of 0.03 the number of subjects to be included per arm is 744
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Advanced colorectal neoplasm detection rate [Time Frame: 2 years] [Designated as safety issue: No]</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1501</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Fecal occult blood testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunochemical fecal occult blood test Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colonoscopy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colonoscopy with sedation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Immunochemical fecal occult blood test And colonoscopy if test is positive</intervention_name>
    <description>Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.</description>
    <arm_group_label>Fecal occult blood testing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colonoscopy with sedation</intervention_name>
    <description>Colonoscopy with sedation</description>
    <arm_group_label>Colonoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 40-75 years, first degree relatives of patients with non-syndromic
             CRC

        Exclusion Criteria:

          -  Personal history of CRC, colorectal adenoma, colorectal polyposis, or inflammatory
             bowel disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Quintero, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fundación Canaria para la Investigación Biomédica Rafael Clavijo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Gimeno-García AZ, Quintero E, Nicolás-Pérez D, Hernández-Guerra M, Parra-Blanco A, Jiménez-Sosa A. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study. Eur J Gastroenterol Hepatol. 2009 Sep;21(9):1062-7. doi: 10.1097/MEG.0b013e3283293797.</citation>
    <PMID>19307978</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2010</study_first_submitted>
  <study_first_submitted_qc>February 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2010</study_first_posted>
  <last_update_submitted>January 7, 2014</last_update_submitted>
  <last_update_submitted_qc>January 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Canaria Rafael Clavijo para la Investigación Biomédica</investigator_affiliation>
    <investigator_full_name>Enrique Quintero</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>FOBT</keyword>
  <keyword>colonoscopy</keyword>
  <keyword>familiar risk</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>advanced adenoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

